Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of D745, D759, and D150 in Healthy Subjects
NCT05928637Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Jul 2023
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of empagliflozin, sitagliptin and liquid metformin (Aspargo Labs) in type 2 diabetes mellitus (T2DM) (6 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area Under the Concentration-time Curve from time zero to the last measurable concentration at Day 29 and Maximum Plasma Concentration at Day 29. Started Jul 2023; status: completed.
02
Drugs
empagliflozinsitagliptinliquid metformin (Aspargo Labs)
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05928637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05928637.